Von Willebrand factor, ABO blood group, and risk of first-ever intracerebral hemorrhage: A prospective nested case-control study.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
11 2020
Historique:
received: 19 11 2019
revised: 14 04 2020
accepted: 03 07 2020
pubmed: 17 7 2020
medline: 22 6 2021
entrez: 17 7 2020
Statut: ppublish

Résumé

Low levels of von Willebrand factor (VWF) were associated with intracerebral hemorrhage (ICH) in a previous study. Persons with blood group O have lower VWF levels than other ABO blood groups. This study aimed to investigate the association between VWF and the risk of ICH in adults, as well as the association between ABO blood group and risk of ICH. This population-based, nested case-control study was conducted using data and blood samples from health examinations between 1985 and 2007. All participants were followed, and cases with first-ever ICH were identified and validated. One or two controls were matched to each case. During a median follow-up time from blood sampling to ICH of 5.6 years, 176 cases with ICH were identified. The mean age at health examination was 57 years; 50% of participants were women. There was an association between hypertension and risk of ICH, but there was no association between VWF level and risk of ICH. There was no association between blood group O and risk of ICH. To our knowledge this is the largest prospective study investigating the association between VWF, ABO blood group and ICH. We found no association between VWF or blood group O and risk of future ICH.

Sections du résumé

BACKGROUND AND PURPOSE
Low levels of von Willebrand factor (VWF) were associated with intracerebral hemorrhage (ICH) in a previous study. Persons with blood group O have lower VWF levels than other ABO blood groups. This study aimed to investigate the association between VWF and the risk of ICH in adults, as well as the association between ABO blood group and risk of ICH.
METHODS
This population-based, nested case-control study was conducted using data and blood samples from health examinations between 1985 and 2007. All participants were followed, and cases with first-ever ICH were identified and validated. One or two controls were matched to each case.
RESULTS
During a median follow-up time from blood sampling to ICH of 5.6 years, 176 cases with ICH were identified. The mean age at health examination was 57 years; 50% of participants were women. There was an association between hypertension and risk of ICH, but there was no association between VWF level and risk of ICH. There was no association between blood group O and risk of ICH.
CONCLUSIONS
To our knowledge this is the largest prospective study investigating the association between VWF, ABO blood group and ICH. We found no association between VWF or blood group O and risk of future ICH.

Identifiants

pubmed: 32673959
pii: S0049-3848(20)30294-2
doi: 10.1016/j.thromres.2020.07.003
pii:
doi:

Substances chimiques

ABO Blood-Group System 0
von Willebrand Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-80

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Kristina Johansson (K)

Department of Public Health and Clinical Medicine, Skellefteå Research Unit, Umeå University, Sweden. Electronic address: kristina.am.johansson@regionvasterbotten.se.

Jan-Håkan Jansson (JH)

Department of Public Health and Clinical Medicine, Skellefteå Research Unit, Umeå University, Sweden.

Lars Johansson (L)

Department of Public Health and Clinical Medicine, Skellefteå Research Unit, Umeå University, Sweden.

Kim Ekblom (K)

Department of Research and Development, Region Kronoberg, Växjö, Sweden; Department of Medical Biosciences, Clinical Chemistry, Umeå University, Sweden.

Marcus M Lind (MM)

Department of Public Health and Clinical Medicine, Skellefteå Research Unit, Umeå University, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH